The GLP-1 market in 2026 looks different from 2024. New entrants, manufacturer pricing moves, and compounded market competition have pushed costs down across the board. Here's what changed and what it means for your wallet.
Disclosure: Some links on this page are affiliate links. Market data reflects May 2026.
What's Dropped
| Category | 2024 Price Range | 2026 Price Range | Change |
|---|---|---|---|
| Compounded sema (low end) | $200–$250/mo | $130–$150/mo | ↓ 35-40% |
| Compounded sema (avg) | $300–$400/mo | $179–$250/mo | ↓ 35-40% |
| Zepbound (LillyDirect) | N/A | $399–$549/mo | New option |
| Brand (list price) | $935–$1,349 | $935–$1,349 | Minimal change |
Why Prices Dropped
1. More Telehealth Competitors
The number of telehealth GLP-1 providers has grown substantially since 2023. More competition means pressure to offer lower prices, better bundling, and introductory deals. Providers that charged $350-400/month in 2024 now compete with options under $200.
2. Compounding Supply Stabilization
As the compounded GLP-1 market matured, bulk API (active pharmaceutical ingredient) pricing has come down. 503B facilities operating at scale can now produce compounded semaglutide at significantly lower per-unit costs than two years ago.
3. LillyDirect Changed the Game
Eli Lilly's decision to sell Zepbound single-dose vials directly to patients through LillyDirect created a brand-name option in the $399-549/month range — well below traditional pharmacy pricing. This put downward pressure on the entire market.
4. Shortage Resolution
The Wegovy and Mounjaro shortages of 2023-2024 created the conditions for the compounded market to flourish. As brand supply improved, compounded providers had to compete harder on price to retain patients who might switch back to brand-name.
What Hasn't Dropped
- Brand list prices — Wegovy and Ozempic list prices have not meaningfully decreased. The savings come from savings cards and direct programs, not list price cuts.
- Insurance copays — if your plan covers GLP-1s, your copay has likely stayed flat or increased slightly.
Where Prices Are Headed
Multiple forces suggest continued downward pressure on GLP-1 pricing: 16+ new GLP-1 drugs in development, potential generic semaglutide after 2031, Chinese manufacturers preparing for global markets, and Medicare coverage expansion increasing demand and leverage. However, the FDA compounding proposal could temporarily push compounded prices up or restrict availability.
Best Current Prices
- Compounded semaglutide prices have dropped 35-40% from 2024 to 2026
- More competition, stabilized supply, and LillyDirect drove the declines
- Brand list prices haven't budged — savings come from programs, not price cuts
- Multiple forces suggest prices will continue falling over the next 2-5 years
- The FDA compounding proposal is the biggest near-term risk to low compounded pricing
- Now is a good time to start — prices are lower than ever with more options available